What question did this study set out to answer?

To determine the diagnostic efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) positron emission tomography in detecting lymphoma lesions, measuring cellular proliferation, and differentiating aggressive from indolent disease.

November 15, 2006Cancer ResearchOpen Access

Molecular Imaging of Proliferation in Malignant Lymphoma

View Full Paper

Ask AI

Bookmark

To determine the diagnostic efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) positron emission tomography in detecting lymphoma lesions, measuring cellular proliferation, and differentiating aggressive from indolent disease.
Prospective study evaluating 34 patients with malignant lymphoma who underwent FLT-PET in addition to standard routine staging.
Conducted emission and transmission PET scanning 60 minutes after intravenous administration of approximately 330 MBq of FLT.
Calculated standardized uptake values (SUV) to quantify tracer uptake and correlated findings with tumor grade and Ki-67 immunohistochemistry proliferation fraction.
FLT-PET identified 490 manifestation sites compared with 420 lesions detected by routine staging procedures.
FLT uptake was significantly higher in aggressive lymphoma (mean SUV 5.9, range 3.2–9.2; n=21) than in indolent lymphoma (mean SUV 2.3, range 1.2–4.5; n=11; P < 0.0001), with an SUV cutoff of 3 accurately separating the subtypes.
Tracer uptake strongly correlated with the Ki-67 proliferation fraction in biopsied lesions based on linear regression analysis (r = 0.84; P < 0.0001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective study demonstrates that fluorothymidine PET distinguishes aggressive from indolent malignant lymphoma, indicating its utility for noninvasive tumor grading.

Cite This Study

Buck et al. (2006) studied this question.

synapsesocial.com/papers/6a1292adf82ba854c366b22f https://doi.org/10.1158/0008-5472.can-06-1955

View Full Paper

Ask AI

Bookmark

Implication

Prospective study demonstrates that fluorothymidine PET distinguishes aggressive from indolent malignant lymphoma, indicating its utility for noninvasive tumor grading.

Molecular Imaging of Proliferation in Malignant Lymphoma

Key Points

Discussion

Implication

Cite This Study

Molecular Imaging of Proliferation in Malignant Lymphoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider